Advertisement
U.S. markets open in 4 hours 4 minutes

Bioventus Inc. (BVS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.3700-0.0200 (-0.46%)
At close: 04:00PM EST
4.3000 -0.07 (-1.60%)
Pre-Market: 04:05AM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close4.3900
Open4.3000
Bid0.0000 x 1000
Ask0.0000 x 800
Day's Range4.3000 - 4.4300
52 Week Range0.8000 - 5.5430
Volume134,726
Avg. Volume161,276
Market Cap275.161M
Beta (5Y Monthly)0.47
PE Ratio (TTM)N/A
EPS (TTM)-2.5600
Earnings DateMar 29, 2024 - Apr 02, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-11% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for BVS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Bioventus Inc.
    Daily – Vickers Top Buyers & Sellers for 05/25/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    9 months agoArgus Research
View more
  • GlobeNewswire

    Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility

    DURHAM, N.C., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it has entered into an Amendment No. 5 (the “Amendment”) to the Credit and Guaranty Agreement, between the Company, Wells Fargo Bank, National Association as Administrative Agent and Collateral Agent, and the Lenders from time to time party thereto, dated as of December 6, 2019 and as amended on August 29, 2021, Octob

  • GlobeNewswire

    Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole

    DURHAM, N.C., Jan. 12, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today the issuance on January 11, 2024 of previously disclosed inducement equity awards to Robert (Rob) Claypoole in connection with this appointment as President and Chief Executive Officer, and Principle Executive Officer of the Company. The awards consist of 375,000 restricted share units and options to purchase 850,000 share

  • GlobeNewswire

    Bioventus Names Robert Claypoole as President and Chief Executive Officer

    Seasoned Leader Brings More than Two Decades of Medical Device Experience and Proven Track Record of Driving Revenue and Operating Margin GrowthDURHAM, N.C., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that its Board of Directors has appointed Robert (Rob) Claypoole as Bioventus’ President and Chief Executive Officer and a member of its Board of Directors, effective January 10, 2